Literature DB >> 20508803

Real-World Data on: Attention Deficit Hyperactivity Disorder Medication Side Effects.

Elisa Cascade1, Amir H Kalali, Sharon B Wigal.   

Abstract

In this article, we provide information on patient-reported side effects from a cross-section of real-world patients. Specifically, data on side effects were tabulated for patients taking one of the following attention deficit hyperactivity disorder medications: amphetamine and dextroamphetamine; atomoxetine; dexmethylphenidate; isdexamfetamine; and methylphenidate. Forty-eight percent of the approximately 325 patients surveyed reported having experienced a side effect as a result of taking an attention deficit hyperactivity disorder medication. Most common side effects mentioned included loss of appetite, sleep problems, and mood disturbances. Only 21 percent of side effects were considered very bothersome or extremely bothersome. Regardless of how bothersome the side effects were, only 20 percent of patients mentioned the side effects to their prescribing physicians.

Entities:  

Keywords:  ADHD; Attention deficit hyperactivity disorder; amphetamine; atomoxetine; dexmethylphenidate; dextroamphetamine; isdexamfetamine; methylphenidate; patient-reported side effect; side effect

Year:  2010        PMID: 20508803      PMCID: PMC2877616     

Source DB:  PubMed          Journal:  Psychiatry (Edgmont)        ISSN: 1550-5952


  4 in total

1.  Side effects of methylphenidate and dexamphetamine in children with attention deficit hyperactivity disorder: a double-blind, crossover trial.

Authors:  D Efron; F Jarman; M Barker
Journal:  Pediatrics       Date:  1997-10       Impact factor: 7.124

2.  Simple pediatric nutritional risk score to identify children at risk of malnutrition.

Authors:  I Sermet-Gaudelus; A S Poisson-Salomon; V Colomb; M C Brusset; F Mosser; F Berrier; C Ricour
Journal:  Am J Clin Nutr       Date:  2000-07       Impact factor: 7.045

3.  Safety and tolerability of methylphenidate in preschool children with ADHD.

Authors:  Tim Wigal; Laurence Greenhill; Shirley Chuang; James McGOUGH; Benedetto Vitiello; Anne Skrobala; James Swanson; Sharon Wigal; Howard Abikoff; Scott Kollins; James McCRACKEN; Mark Riddle; Kelly Posner; Jaswinder Ghuman; Mark Davies; Ben Thorp; Annamarie Stehli
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2006-11       Impact factor: 8.829

Review 4.  Efficacy and safety limitations of attention-deficit hyperactivity disorder pharmacotherapy in children and adults.

Authors:  Sharon B Wigal
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

  4 in total
  5 in total

1.  Aberrant glutamate signaling in the prefrontal cortex and striatum of the spontaneously hypertensive rat model of attention-deficit/hyperactivity disorder.

Authors:  Erin M Miller; Francois Pomerleau; Peter Huettl; Greg A Gerhardt; Paul E A Glaser
Journal:  Psychopharmacology (Berl)       Date:  2014-02-28       Impact factor: 4.530

2.  Minimizing adverse events while maintaining clinical improvement in a pediatric attention-deficit/hyperactivity disorder crossover trial with dextroamphetamine and methylphenidate.

Authors:  Bjørn E Ramtvedt; Henning S Aabech; Kjetil Sundet
Journal:  J Child Adolesc Psychopharmacol       Date:  2014-03-25       Impact factor: 2.576

3.  ADHD, Multimodal Treatment, and Longitudinal Outcome: Evidence, Paradox, and Challenge.

Authors:  Stephen P Hinshaw; L Eugene Arnold
Journal:  Wiley Interdiscip Rev Cogn Sci       Date:  2015-01

Review 4.  The long-term outcomes of interventions for the management of attention-deficit hyperactivity disorder in children and adolescents: a systematic review of randomized controlled trials.

Authors:  Jack Parker; Gill Wales; Nevyne Chalhoub; Val Harpin
Journal:  Psychol Res Behav Manag       Date:  2013-09-17

Review 5.  From Clinical Application to Cognitive Enhancement: The Example of Methylphenidate.

Authors:  Francesco Paolo Busardò; Chrystalla Kyriakou; Luigi Cipolloni; Simona Zaami; Paola Frati
Journal:  Curr Neuropharmacol       Date:  2016       Impact factor: 7.363

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.